Stocks Health care LTRN
NASDAQ · Health careLantern Pharma Inc. (LTRN)
It posted a net loss of $18.7M. In fiscal 2025 capital spending exceeded operating cash flow by $15.7M. At June 30, 2026 it held $6.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Lantern Pharma Inc.
- Net worth
- Lantern Pharma Inc. has a market value (market cap) of $6.1M at the latest share price, and shareholders' equity of -$3.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $15.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lantern Pharma Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Lantern Pharma Inc. does
Lantern Pharma Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LTRN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$17.1M | -$1.57 | -$15.7M |
| 2024 | n/a | -$20.8M | -$1.93 | -$17.8M |
| 2023 | n/a | -$16M | -$1.47 | -$14.4M |
| 2022 | n/a | -$14.3M | -$1.31 | -$12.8M |
| 2021 | n/a | -$12.4M | -$1.13 | -$10.6M |
| 2020 | n/a | -$5.9M | -$1.37 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Lantern Pharma Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026
- September 30, 2026Material agreement8-KLantern Pharma raised approximately $4.0 million in gross proceeds through a registered direct offering and concurrent private placement of warrants.
- September 24, 2026
- September 23, 2026
- August 14, 2026
- August 14, 2026
- August 4, 2026Passive stake (5% or more) SCHEDULE 13G
- August 3, 2026
- July 23, 2026Passive stake changed SCHEDULE 13G/A
- June 12, 2026IPO registration S-1
Insider trades
What the people running Lantern Pharma Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 12, 2026 | Keyser D JeffreyDirector | Bought | 48,544 | $100K |
| May 12, 2026 | Schalop Lee TroyDirector | Bought | 48,544 | $100K |
Who owns LTRN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Cavu Management, LP13D, may seek influence with 13 related filers | 11.8% | March 1, 2024 |
| Empery Asset Management, LP13G, passive with 1 related filers | 9.99% | August 4, 2026 |
| Thomas A. Satterfield, Jr.13G, passive | 7.6% | July 23, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 142,847 shares in total, about $68.7K at the last price.
| Holder | Shares |
|---|---|
| Keyser D JeffreyDirector | 94,303 |
| Schalop Lee TroyDirector | 48,544 |
Questions about LTRN
What does Lantern Pharma Inc. do?
Lantern Pharma Inc. is a company in the Health care sector, listed on NASDAQ as LTRN. Its shares trade on NASDAQ under the ticker LTRN.
What is Lantern Pharma Inc.'s net worth?
Lantern Pharma Inc. has a market value (market cap) of $6.1M at the latest share price, and shareholders' equity of -$3.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lantern Pharma Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.7M.
When did Lantern Pharma Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from October 1, 2026.
When is Lantern Pharma Inc.'s next earnings report?
Lantern Pharma Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LTRN with
Follow LTRN
Get an email when Lantern Pharma Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lantern Pharma Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.